Experts unravel crucial myths and facts about the Nipah virus, an emerging threat to global health

The Nipah virus (NiV), a highly lethal zoonotic pathogen, continues to represent a serious global health concern, especially in Ásia regions. Desde its discovery has caused sporadic outbreaks with alarming mortality rates, becoming a constant focus of research and epidemiological surveillance.
The infectious nature of Nipah, which can be transmitted from animals to humans and, in some cases, from person to person, requires in-depth understanding to mitigate risks. The complexity of its life cycle and the absence of specific treatments or licensed vaccines amplify the urgency in monitoring and controlling its spread.
With the rapid circulation of information in the digital age, accurate knowledge about NiV is essential to combat panic and false information. It is essential to discern between scientific reality and rumors that could compromise public health actions. Entre the crucial points to be understood are:

- Zoonotic origin, with fruit bats as natural hosts.
- The high mortality rate in human infections.
- The lack of a vaccine or specific antiviral treatment to date.
In this scenario, the dissemination of evidence-based information becomes an indispensable tool to protect communities and strengthen global defenses against future health emergencies.
The Nipah virus: an emerging zoonosis and its danger
The Nipah virus, first identified in 1998 during an outbreak of encephalitis in pig farmers at Malásia and Singapura, is classified as a paramyxovirus and has emerged as a pathogen of concern. Sua origin is in the fruit bats of the Pteropodidae family, specifically the genusPteropus, which are its natural hosts and carry it without developing the disease, serving as reservoirs of the virus.
The disease caused by NiV, Nipah encephalitis, manifests with a wide range of symptoms, from asymptomatic infection to an acute respiratory condition and fatal encephalitis. The fatality rate varies considerably, ranging between 40% and 75% in documented outbreaks, depending on factors such as local response capacity and the virulence of the strain. Esse high mortality rate highlights the severity of the threat that the virus poses to public health.
Symptoms and disease progression in patients
The initial phase of Nipah infection can be misleading, presenting general and non-specific symptoms that are easily confused with other common diseases, making early diagnosis difficult. Patients often report fever, severe headache, myalgia, vomiting, and sore throat, signs that do not immediately indicate the underlying severity of the condition.
However, the disease tends to progress rapidly to a more serious clinical condition, characterized by severe neurological symptoms. In a matter of days or weeks, those infected can develop acute encephalitis, manifested by drowsiness, disorientation, seizures and, in many cases, coma, leading to fatal outcomes if intensive medical support is not provided.
Sources of infection and pathogen transmission routes
The main source of infection for humans is direct contact with infected animals, especially pigs, which can develop a serious respiratory illness and transmit the virus through respiratory secretions, urine and other body fluids. Proximity to sick animals on farms or markets has been a key factor in past outbreaks.
In addition to pigs, other domestic animals, such as horses, goats, sheep, cats and dogs, can also be infected, although their participation in the transmission chain to humans is less studied. Surveillance on farms and the adoption of biosecurity measures are crucial to breaking this chain.
Ingestion of food or products contaminated with bat body fluids, such as unpasteurized date palm sap or fruit bitten by the animals, represents another significant route of contamination. Essa mode of transmission is particularly prevalent in regions where these eating habits are common.
Person-to-person transmission of Nipah is a concern, observed mainly in hospital settings, where close contact with infected patients, their secretions and body fluids can result in new infections. Profissionais healthcare and family caregivers are at increased risk, highlighting the importance of personal protective equipment and strict infection control protocols.
Challenges in identifying and developing effective treatments
Identification of the Nipah virus presents significant challenges, as its initial symptoms are indistinguishable from other febrile illnesses common in endemic regions, such as malaria or Japanese encephalitis. Essa non-specificity delays diagnosis and implementation of containment measures, increasing the risk of transmission. Confirmation of infection requires specific laboratory tests, such as real-time RT-PCR and ELISA assays for antibody detection, which are not always readily available in all affected areas, especially in rural communities with limited healthcare infrastructure. Essa diagnostic gap hampers epidemiological surveillance and rapid response to outbreaks, making containment more complex and mortality potentially higher. Além In addition, the absence of a licensed specific antiviral treatment for the
Demystifying rumors: truths and untruths about Nipah
In a scenario of uncertainty about emerging diseases, the proliferation of false information can be as dangerous as the pathogen itself, generating panic and diverting resources from effective public health actions. It is crucial that the public trusts only official and recognized sources for accurate information about the Nipah virus.
A common rumor is that the Nipah virus is easily transmitted through the air, in a similar way to the common flu, which does not correspond to scientific reality. The main route of transmission to humans involves direct contact with bodily fluids from infected animals, such as sick bats or pigs, or ingestion of food contaminated with bat secretions.
Another widely publicized untruth is the existence of an approved vaccine available for humans against Nipah. While research and development of immunizers are ongoing and showing promising results in experimental phases, there is currently no licensed vaccine widely available for use in humans.
There is also the misperception that Nipah is a completely new and unknown virus. Contudo, the virus was first identified in 1998 and has since been the subject of extensive research and studies. Embora rare, its history of recurrent outbreaks makes it a known threat and studied by the international scientific community.
Epidemiological prevention and surveillance strategies
Continuous epidemiological surveillance and early case detection are crucial to contain the spread of the Nipah virus and prevent large outbreaks. Programas of animal and human health monitoring, combined with rapid alert systems, allow for an agile response to any sign of infection, isolating cases and investigating contacts.
Education and public awareness play a vital role in prevention, guiding communities about risks and protective measures. Evitar contact with sick bats and pigs, not consuming raw date palm products and washing the fruits thoroughly before consumption are essential practices to minimize exposure to the virus.
Furthermore, the implementation of strict hygiene practices in hospital environments and the use of personal protective equipment by healthcare professionals are essential. Essas actions seek to prevent nosocomial transmission and protect frontline workers against infection.
Persistent threat and international mobilization
The persistence of the Nipah virus, with its pandemic potential and the lack of specific interventions, keeps the international community on high alert. Organizações as well as Organização Mundial of Saúde (WHO) and global research agencies are actively engaged in coordinating efforts to strengthen surveillance, promote research and development of vaccines and treatments, and enhance the response capacity of countries at risk. International collaboration is crucial to address this cross-border threat and protect global health against the devastating impact of future epidemiological emergencies. The experience accumulated over the years, with controlled outbreaks and the advancement of science, offers a path to developing more effective containment and mitigation strategies, reinforcing the importance of continued investment in research and preparedness.






